Clinical Trials · NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 43
- Start date
- Jul 2023
- Locations
- 5 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943